|
 Bristol-Myers disclosed plans for the exploratory 30-patient trial
testing its three-drug combination with Sovaldi in an interview with
Reuters. Eric Hughes, the leader of Bristol's global hepatitis
program, said the details were due to be posted on the
clinicaltrials.gov website next week.
Sovaldi's $84,000 price tag for a 12-week treatment has spurred
outrage among insurers, state health officials and lawmakers who
fear the cost of treating millions of Americans with the progressive
liver disease will top $250 billion. Insurers are pushing Gilead's
rivals to offer lower prices when their hepatitis C medicines reach
the market.
Using the drug for a shorter course of treatment could, in theory,
lower the cost, even when combined with Bristol's therapies. Rivals
Merck & Co and AbbVie are also racing to develop next-generation
hepatitis C treatments that cure most people of the virus in a
shorter time frame.
But drug pricing experts expect Gilead and its rivals may still
argue that the quicker cure represents a value to patients,
buffering any steep price reductions.
"The position and concept of pharma is not ingredient costs or
duration of treatment cost. Pharma is looking at it as cost per
cure," said John Whang, co-president of Reimbursement Intelligence,
which works with pharmaceutical companies and payers to help
determine prices for medicines.
The cost could come down, he said, "but it's not going to be
proportionate to the degree that the duration of treatment
shortens."
The new generation of oral drugs being developed by several
companies has raised hepatitis C cure rates to well above 90 percent
from about 75 percent without the need for interferon or ribavirin,
which caused miserable side effects that led many patients to delay
or drop treatment. The drugs in clinical trials have already cut
treatment time to 12 weeks from 24 to 48 weeks.
"We got rid of the tolerability problem. We got rid of the efficacy
problem. Now there is a tremendous drive to get down to shorter
treatment durations," Bristol-Myers' Hughes said in a telephone
interview.
REVIVING A SOVALDI COMBO
Bristol's plan essentially revives an effort to test its drugs in
combination with Sovaldi. It previously tested a single compound
with Sovaldi, achieving cure rates close to 100 percent in 12 weeks.
But Gilead scrapped further testing in 2012, as it preferred to
develop its own combination without a partner.
Gilead's pill that combines Sovaldi with its ledipasvir is expected
to gain U.S. approval this year for therapies of eight or 12 weeks,
depending on the patient. The company is also testing the
combination as a six-week treatment.
[to top of second column] |
The go-it-alone strategy has already paid off as Gilead was first to
market with Sovaldi, breaking pharmaceutical industry sales records
with $2.3 billion in sales within a few months.
The new study, set to begin in late July, will test a trio of
Bristol drugs with Sovaldi in previously untreated patients with the
most common Genotype 1 form of the virus. It will involve two groups
of 15 patients each - one getting four weeks of treatment and the
other six.
If Bristol can demonstrate cure rates in excess of 90 percent in
four weeks, it plans to conduct larger trials with a more diverse
patient population.
"We'll see what the data says," Hughes said. "Taking this forward
will be a very exciting thing."
With Gilead not involved in the effort, Bristol will pay full price
for Sovaldi to conduct the trial.
Bristol would not discuss potential pricing of its regimen, since
its drugs are not approved. But if treatment can be cut to four
weeks from 12, the Sovaldi portion would be closer to $28,000.
Other rivals are also advancing efforts to compete in what is
expected to be a huge market.
Merck this month agreed to pay $3.85 billion to acquire Idenix
Pharmaceuticals Inc with the hope that combining the two companies'
most promising drugs will produce cures in four to six weeks across
the full spectrum of genotypes.
U.S. and European health regulators in the last week said they would
accelerate their reviews of AbbVie's four-drug regimen, meaning it
could be vying for market share by early next year.
(Reporting by Bill Berkrot; Editing by Michele Gershberg and Douglas
Royalty)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
